<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <title>Combination Drug Development Incentive Act of 2015</title>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. CHAFFETZ:H.R. 406.Congress has the power to enact this legislation pursuantto the following:Clause 3 of Section 8 of Article I of the Constitution: Toregulate Commerce with foreign Nations, and among the severalStates, and with the Indian Tribes;Clause 18 of Section 8 of Article I of the Constitution: Tomake all Laws which shal be necessary and proper for carryinginto Execution the foregoing Powers, and all other Powersvested by this Constitution in the Government of the UnitedStates, or in any Department or Officer therof.[Page H430]</pre>]]></constitutionalAuthorityStatementText>
    <billType>HR</billType>
    <laws />
    <recordedVotes />
    <titles>
      <item>
        <title>Combination Drug Development Incentive Act of 2015</title>
        <parentTitleType />
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <title>To amend section 505 of the Federal Food, Drug, and Cosmetic Act to provide incentives for the development of new combination drugs.</title>
        <parentTitleType />
        <titleType>Official Title as Introduced</titleType>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <title>Combination Drug Development Incentive Act of 2015</title>
        <parentTitleType />
        <titleType>Display Title</titleType>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <originChamber>House</originChamber>
    <amendments />
    <subjects>
      <billSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
        <legislativeSubjects>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
          <item>
            <name>Product development and innovation</name>
          </item>
        </legislativeSubjects>
      </billSubjects>
    </subjects>
    <introducedDate>2015-01-20</introducedDate>
    <version>1.0.0</version>
    <cosponsors />
    <committees>
      <billCommittees>
        <item>
          <name>Energy and Commerce Committee</name>
          <subcommittees>
            <item>
              <name>Health Subcommittee</name>
              <activities>
                <item>
                  <date>2015-01-23T18:15:41Z</date>
                  <name>Referred to</name>
                </item>
              </activities>
              <systemCode>hsif14</systemCode>
            </item>
          </subcommittees>
          <activities>
            <item>
              <date>2015-01-20T17:01:10Z</date>
              <name>Referred to</name>
            </item>
          </activities>
          <chamber>House</chamber>
          <type>Standing</type>
          <systemCode>hsif00</systemCode>
        </item>
      </billCommittees>
    </committees>
    <actions>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
      <item>
        <actionDate>2015-01-23</actionDate>
        <committee>
          <systemCode>hsif14</systemCode>
          <name>Health Subcommittee</name>
        </committee>
        <links />
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionCode>H11100</actionCode>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <actionDate>2015-01-20</actionDate>
        <committee>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
        </committee>
        <links />
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionCode>Intro-H</actionCode>
        <text>Introduced in House</text>
        <actionDate>2015-01-20</actionDate>
        <committee />
        <links />
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionCode>1000</actionCode>
        <text>Introduced in House</text>
        <actionDate>2015-01-20</actionDate>
        <committee />
        <links />
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
      <actionTypeCounts>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInHouse>1</introducedInHouse>
        <billReferrals>1</billReferrals>
        <introducedInTheHouse>1</introducedInTheHouse>
      </actionTypeCounts>
    </actions>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <cboCostEstimates />
    <committeeReports />
    <createDate>2015-01-21T04:46:23Z</createDate>
    <calendarNumbers />
    <latestAction>
      <actionDate>2015-01-23</actionDate>
      <links />
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <congress>114</congress>
    <updateDate>2017-10-27T17:58:55Z</updateDate>
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p><b>Combination Drug Development Incentive Act of 2015</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to provide a five-year marketing exclusivity period to a new drug approved by the Food and Drug Administration that is a novel combination of active ingredients. The application for the combination drug must contain reports of new clinical investigations that are essential to approval and were conducted or sponsored by the applicant. Currently, a new drug that includes an active ingredient that has already been approved is provided a three-year marketing exclusivity period.</p> <p>]]></text>
          <lastSummaryUpdateDate>2015-04-07T16:12:36Z</lastSummaryUpdateDate>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <actionDate>2015-01-20</actionDate>
          <actionDesc>Introduced in House</actionDesc>
          <updateDate>2015-01-20T05:00:00Z</updateDate>
        </item>
      </billSummaries>
    </summaries>
    <relatedBills />
    <sponsors>
      <item>
        <bioguideId>C001076</bioguideId>
        <party>R</party>
        <firstName>Jason</firstName>
        <state>UT</state>
        <middleName />
        <lastName>Chaffetz</lastName>
        <byRequestType />
        <fullName>Rep. Chaffetz, Jason [R-UT-3]</fullName>
        <district>3</district>
        <identifiers>
          <lisID>1956</lisID>
          <bioguideId>C001076</bioguideId>
          <gpoId>8191</gpoId>
        </identifiers>
      </item>
    </sponsors>
    <notes />
    <billNumber>406</billNumber>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

